Access the full text.
Sign up today, get DeepDyve free for 14 days.
Allen Williams, Li Li, Bao Nguyen, P. Brown, M. Levis, D. Small (2012)
Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.Blood, 120 15
T. Schroeder, J. Fröbel, Ron-Patrick Cadeddu, A. Czibere, Ariane Dienst, E. Zipperer, U. Platzbecker, G. Bug, L. Uharek, R. Fenk, U. Germing, N. Kröger, R. Haas, G. Kobbe (2012)
Salvage Therapy with Azacitidine Increases Regulatory T Cells in Patients with AML or MDS and Early Relapse After Allogeneic Blood Stem Cell TransplantationBlood, 120
V. Rocha, M. Labopin, A. Ruggeri, D. Blaise, B. Rio, J. Cornelissen, N. Milpied, L. Tucunduva, A. Nagler, M. Mohty, E. Gluckman (2012)
Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning RegimenBiology of Blood and Marrow Transplantation, 19
M. Low, G. Gregory (2012)
Passenger lymphocyte syndrome after lung transplant.Blood, 120 20
M. Lima, S. Parmar, Julianne Chen, S. Giralt, G. Rondon, U. Popat, A. Alousi, Hans Lee, Glenda Woodworth, C. Hosing, E. Shpall, P. Kebriaei, G. Manero, R. Champlin, R. Saliba (2012)
Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Blood, 120
M. Stelljes, U. Krug, D. Beelen, J. Braess, M. Sauerland, A. Heinecke, T. Sauer, P. Tschanter, Gabriela Thoennissen, H. Kolb, A. Reichle, E. Holler, R. Schwerdtfeger, R. Arnold, C. Scheid, C. Müller-Tidow, B. Woermann, W. Hiddemann, W. Berdel, T. Büchner (2012)
Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs AnalysisBlood, 120
G. Thanarajasingam, Haesook Kim, C. Cutler, V. Ho, J. Koreth, E. Alyea, J. Antin, R. Soiffer, P. Armand (2012)
Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.Blood, 120
S. Blum, A. Angelillo-Scherrer (2012)
Block of red blood cell maturation in acute erythroid leukemia.Blood, 120 10
J. Keuschnigg, D. Tvorogov, K. Elima, M. Salmi, K. Alitalo, T. Salminen, S. Jalkanen (2012)
PV-1 is recognized by the PAL-E antibody and forms complexes with NRP-1.Blood, 120 1
K. Sockel, C. Schönefeldt, S. Sopper, M. Wermke, M. Schmitz, G. Ehninger, M. Bornhäuser, D. Wolf, U. Platzbecker (2012)
Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell TransplantationBlood, 120
M. Lupo-Stanghellini, M. Carrabba, E. Sala, S. Mastaglio, M. Marcatti, M. Tassara, A. Assanelli, C. Messina, K. Fleischhauer, S. Marktel, E. Guggiari, F. Lunghi, S. Gattillo, L. Bellio, M. Coppola, C. Bonini, C. Bordignon, C. Corti, J. Peccatori, M. Bernardi, F. Ciceri (2012)
Haploidentical Transplantation Outcome Is Not Inferior to Standard Matched Related and Unrelated Donor Transplantation: An Intention-to-Treat Analysis of 241 Patients with Acute Myeloid LeukemiaBlood, 120
E. Atallah, T. Pedersen, E. Warlick, Anne Dircks, D. Weisdorf, M. Horowitz, J. Rizzo (2012)
The Outcome of Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) in Adults ≥65 Years of Age: First Report of the Coverage with Evidence Development (CED) in Medicare BeneficiariesBlood, 120
S. Devine, K. Owzar, W. Blum, D. DeAngelo, R. Stone, Jack Hsu, R. Champlin, Yi-Bin Chen, R. Vij, J. Slack, R. Soiffer, R. Larson, T. Shea, V. Hárs, E. Bennett, Sada Spangle, S. Giralt, S. Carter, M. Horowitz, C. Linker, E. Alyea (2012)
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502Blood, 120
H. Baldomero, M. Aljurf, L. Bouzas, A. Gratwohl, Y. Kodera, J. Lipton, J. Madrigal, Lida Minako, N. Novitzky, M. Pasquini, J. Passweg, A. Seber, J. Szer, D. Niederwieser (2012)
Global Trends in Hematopoietic Cell Transplantation.Blood, 120
Hematopoietic stem cell transplantation (HSCT) is a developing treatment modality, continuously being adapted to disease-specific requirements, and, even more successfully, to the tolerability in a growing target population. Allogeneic HSCT, in particular, is now accessible as a curative treatment for patients that would have been allocated to palliative concepts 1 or 2 decades ago. However, modern pharmacotherapy of neoplastic diseases is advancing, taking advantage of the increasing insight into cancer biology. Therefore, the role of HSCT in the treatment of hematologic malignancies has to be defined and reconsidered in a continuous fashion. At the ASH Meeting 2012, nearly 900 abstracts covered the field of allogeneic HSCT. The short list of abstracts reviewed here was selected according to the authors’ perception of a particular clinical impact. It is aimed to cover the most relevant issues an HSCT-physician is faced with in clinical practice in 2013, namely the management of the elderly patient (typically with acute myeloid leukemia or myelodysplastic syndromes), the limitations regarding access to a suitable donor, and the management of relapse and the most important cause of nonrelapse mortality, graft versus host disease, after allogeneic HSCT.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 21, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.